Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition.
The clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients had complete recovery from their respective severe/critical condition and were released from the hospital after an average of 5.5 days (severe) and 8.5 days (critical), following administration of Allocetra, at which time they were all COVID-19 PCR negative. There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated.
АПДЕЙТ: Запустили вторую фазу испытаний
АПДЕЙТ-2: Первые два пациента получили препарат
АПДЕЙТ-3 - 3 декабря
Allocetra-OTS in COVID-19, Phase II
АПДЕЙТ-4 - 3 февраля